Connection Between Epigenome, Selective Mutability, Evolution, and Human Disease
Li, Harris et al., PLoS Genetics
Researchers at the Baylor College of Medicine and elsewhere propose a "connection between the epigenome, selective mutability, evolution, and human disease" based on the findings of their study on associations of structural mutability with germline DNA methylation and with non-allelic homologous recombination mediated by low-copy repeats. "Combined evidence from four human sperm methylome maps, human genome evolution, structural polymorphisms in the human population, and previous genomic and disease studies consistently points to a strong association of germline hypomethylation and genomic instability," the Baylor-led team writes.
Anthem BCBS to Cover XDx's AlloMap in Stable Heart Transplant Patients
June 08, 2011
"AlloMap molecular expression testing is considered medically necessary as a non-invasive method of determining the risk of rejection in heart transplant recipients between one and five years post transplant," Anthem wrote in an updated medical policy.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.
New to GenomeWeb? Register quickly here.
Related Stories
- Dx Focus: Quest Simplexa C. Diff Assay Gets FDA OK; XDx Begins AlloMap Testing in Germany
April 12, 2012 / PCR Insider - Highmark to Cover XDx's AlloMap Test
November 8, 2011 / GenomeWeb Daily News - XDx's AlloMap Heart-Rejection Test Racks Up Payor Wins, But Walls Remain
August 17, 2011 / The Sample - XDx Says Lack of Financial Incentives Blocking Physician Uptake of Heart Transplant Rejection Test
April 13, 2011 / Pharmacogenomics Reporter - Aetna Deems XDx AlloMap Test 'Medically Necessary' for Monitoring Heart Transplant Patients
March 9, 2011 / Pharmacogenomics Reporter